This report inspired the revival of DeltaRex-G and the USFDA authorized opening of Blessed: Expanded Access for DeltaRex-G for an intermediate size population with advanced pancreatic adenocarcinoma and sarcoma, and Individual Patient Use of DeltaRex-G as adjuvant therapy for early-stage HR + HER2+ invasive breast carcinoma and triple negative breast carcinoma (Chawla et al., 2022). This evidence concerns the gene ERBB2 and sarcoma.